文献速递糖尿病

通过尿液蛋白质组学早期检测糖尿病肾病及后续螺内酯干预延缓进展(PRIORITY):一项前瞻性观察研究及嵌入式随机安慰剂对照试验

Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2020-03-02

PRIORITY研究纳入1775例尿白蛋白正常、肾功能保留的2型糖尿病患者,用CKD273尿液蛋白质组分类器分为高风险(>0.154)和低风险(≤0.154)。中位随访2.51年,高风险组进展至微量白蛋白尿的风险显著高于低风险组(HR 2.48,95%CI 1.80-3.42)。嵌入式随机试验中,螺内酯25mg每日一次与安慰剂相比未显著降低微量白蛋白尿发生率(HR 0.81,95%CI 0.49-1.34,p=0.41)。

要点

  • CKD273高风险评分与2型糖尿病患者的微量白蛋白尿进展风险增加相关(HR 2.48)。
  • 螺内酯25mg每日一次未显著预防高风险患者的微量白蛋白尿进展(HR 0.81,p=0.41)。
  • 螺内酯组高钾血症(血钾>5.5 mmol/L)发生率13%,安慰剂组4%。

核心结论

  • 在尿白蛋白正常的2型糖尿病患者中,CKD273尿液蛋白质组分类器高风险评分与中位2.5年内进展至微量白蛋白尿的风险增加相关,且独立于临床特征。
  • 螺内酯未能预防高风险患者的微量白蛋白尿进展。

研究设计与样本

  • 多中心、前瞻性、观察性研究,嵌套随机安慰剂对照试验(PRIORITY),从十个欧洲国家的15个专科中心招募2型糖尿病、尿白蛋白排泄正常且肾功能保留的患者。
  • 观察队列1775例均接受CKD273分类器检测,高风险(评分>0.154)者进入随机试验,按1:1随机分配至螺内酯25 mg每日一次或匹配安慰剂。
  • 试验队列209例(螺内酯组102例,安慰剂组107例),主要终点为观察队列中确诊微量白蛋白尿的发生。

主要发现

  • 中位随访2.51年(IQR 2.0-3.0),高风险组216例中61例(28%)进展至微量白蛋白尿,低风险组1559例中139例(9%)进展(HR 2.48,95%CI 1.80-3.42;p<0.0001,经基线变量校正)。
  • 高风险组184例中48例(26%)出现肾功能受损(eGFR<60 mL/min per 1.73 m²),低风险组1423例中119例(8%)出现(HR 3.50;95%CI 2.50-4.90,经基线变量校正)。
  • 高风险组216例中42例(19%)出现eGFR较基线下降30%(事后终点),低风险组1559例中62例(4%)出现(HR 5.15,95%CI 3.41-7.76;p<0.0001,经基线eGFR和UACR校正)。
  • 意向治疗试验队列中,安慰剂组107例中35例(33%)发生微量白蛋白尿,螺内酯组102例中26例(25%)发生(HR 0.81,95%CI 0.49-1.34;p=0.41)。
  • 安全性分析中,螺内酯组102例中13例(13%)出现血钾>5.5 mmol/L,安慰剂组107例中4例(4%)出现;螺内酯组3例(3%)出现男性乳房发育,安慰剂组无。

关键数值与推荐

  • CKD273分类器高风险定义为评分>0.154,低风险定义为≤0.154。
  • 螺内酯剂量为25 mg每日一次。
  • 主要终点为确诊微量白蛋白尿的发生。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Microalbuminuria is an early sign of kidney disease in people with diabetes and indicates increased risk of cardiovascular disease. We tested whether a urinary proteomic risk classifier (CKD273) score was associated with development of microalbuminuria and whether progression to microalbuminuria could be prevented with the mineralocorticoid receptor antagonist spironolactone. METHODS: In this multicentre, prospective, observational study with embedded randomised controlled trial (PRIORITY), we recruited people with type 2 diabetes, normal urinary albumin excretion, and preserved renal function from 15 specialist centres in ten European countries. All participants (observational cohort) were tested with the CKD273 classifier and classified as high risk (CKD273 classifier score >0·154) or low risk (≤0·154). Participants who were classified as high risk were entered into a randomised controlled trial and randomly assigned (1:1), by use of an interactive web-response system, to receive spironolactone 25 mg once daily or matched placebo (trial cohort). The primary endpoint was development of confirmed microalbuminuria in all individuals with available data (observational cohort). Secondary endpoints included reduction in incidence of microalbuminuria with spironolactone (trial cohort, intention-to-treat population) and association between CKD273 risk score and measures of impaired renal function based on estimated glomerular filtration rate (eGFR; observational cohort). Adverse events (particularly gynaecomastia and hyperkalaemia) and serious adverse events were recorded for the intention-to-treat population (trial cohort). This study is registered with the EU Clinical Trials Register (EudraCT 20120-004523-4) and ClinicalTrials.gov (NCT02040441) and is completed. FINDINGS: Between March 25, 2014, and Sept 30, 2018, we enrolled and followed-up 1775 participants (observational cohort), 1559 (88%) of 1775 participants had a low-risk urinary proteomic pattern and 216 (12%) had a high-risk pattern, of whom 209 were included in the trial cohort and assigned to spironolactone (n=102) or placebo (n=107). The overall median follow-up time was 2·51 years (IQR 2·0-3·0). Progression to microalbuminuria was seen in 61 (28%) of 216 high-risk participants and 139 (9%) of 1559 low-risk participants (hazard ratio [HR] 2·48, 95% CI 1·80-3·42; p<0·0001, after adjustment for baseline variables of age, sex, HbA1c, systolic blood pressure, retinopathy, urine albumin-to-creatinine ratio [UACR], and eGFR). Development of impaired renal function (eGFR <60 mL/min per 1·73 m2) was seen in 48 (26%) of 184 high-risk participants and 119 (8%) of 1423 low-risk participants (HR 3·50; 95% CI 2·50-4·90, after adjustment for baseline variables). A 30% decrease in eGFR from baseline (post-hoc endpoint) was seen in 42 (19%) of 216 high-risk participants and 62 (4%) of 1559 low-risk participants (HR 5·15, 95% CI 3·41-7·76; p<0·0001, after adjustment for basline eGFR and UACR). In the intention-to-treat trial cohort, development of microalbuminuria was seen in 35 (33%) of 107 in the placebo group and 26 (25%) of 102 in the spironolactone group (HR 0·81, 95% CI 0·49-1·34; p=0·41). In the safety analysis (intention-to-treat trial cohort), events of plasma potassium concentrations of more than 5·5 mmol/L were seen in 13 (13%) of 102 participants in the spironolactone group and four (4%) of 107 participants in the placebo group, and gynaecomastia was seen in three (3%) participants in the spironolactone group and none in the placebo group. One patient died in the placebo group due to a cardiac event (considered possibly related to study drug) and one patient died in the spironolactone group due to cancer, deemed unrelated to study drug. INTERPRETATION: In people with type 2 diabetes and normoalbuminuria, a high-risk score from the urinary proteomic classifier CKD273 was associated with an increased risk of progression to microalbuminuria over a median of 2·5 years, independent of clinical characteristics. However, spironolactone did not prevent progression to microalbuminuria in high-risk patients. FUNDING: European Union Seventh Framework Programme.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Tofte N, Lindhardt M, Adamova K, et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol. 2020. PMID: 32135136. doi:10.1016/S2213-8587(20)30026-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。